PHASE IIB, MULTICENTER, RANDOMIZED, OPEN LABEL TRIAL OF CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME INJECTION VERSUS CYTARABINE AND DAUNORUBICIN IN PATIENTS WITH UNTREATED AML 60-75 YEARS OF AGE.

Trial Profile

PHASE IIB, MULTICENTER, RANDOMIZED, OPEN LABEL TRIAL OF CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME INJECTION VERSUS CYTARABINE AND DAUNORUBICIN IN PATIENTS WITH UNTREATED AML 60-75 YEARS OF AGE.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Cytarabine/daunorubicin (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celator Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2016 Primary endpoint (Remission rate (Complete remission rate following 1st induction))has been met, as per Celator Pharmaceuticals media release.
    • 25 Apr 2016 Results were presented at the AMCP Managed Care & Specialty Pharmacy Annual Meeting, as per Celator Pharmaceuticals media release.
    • 25 Apr 2016 Results published in Celator Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top